Background {#Sec1}
==========

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder whose onset is mostly sporadic \[[@CR1]\]. The genetic background has a major role in AD, and DNA variants may contribute, ranging from predisposing risk factors (having from medium to large effect size, such as the ε4 allele of the *APOE* gene) \[[@CR2]\] to full penetrant causal mutations in a few genes, namely presenilins (*PSEN1* and *PSEN2*) and the amyloid-β (A4) precursor protein (*APP*) \[[@CR3], [@CR4]\]. *PSEN1/2* and *APP* gene mutations have been linked to early-onset, autosomal dominant familial forms of Alzheimer's disease (FAD) \[[@CR5], [@CR6]\]. Recently, large-scale whole-exome sequencing has found rare variants reported to contribute to AD risk, such as in the *PLCG2*, *ABI3*, and *TREM2* genes \[[@CR7]\]. These findings indicate the involvement in familiar forms of AD of variants belonging to genes other than *PSEN1/2* and *APP*, which may have a causal or predisposing role, as recently reported for *SORL1* gene \[[@CR8]\].

We report an Italian family with several cases of AD (having an onset between 60 and 70 years) negative for *PSEN1/2* or *APP* mutations and whose available affected members were found to bear *SEZ6* gene rare missense variant R615H. We describe the genetic, *in vitro*, and *in vivo* findings further supporting a role for *SEZ6* in AD molecular mechanisms.

Methods {#Sec2}
=======

Family and patient description {#Sec3}
------------------------------

The family's pedigree is reported in Fig. [1](#Fig1){ref-type="fig"}. We extracted DNA for exome sequencing analysis from the members indicated by the code PR (seven subjects). We had clinical details about three generations after the founder. Ten dementia cases were reported in the whole pedigree, with an additional member having Parkinson's disease. The age of onset of neurodegenerative disorders ranged from 60 to 70 years. In the first generation, one early-onset dementia case was reported (age at death, 48 years). In the second generation, 8 of 25 siblings (32%) were diagnosed with AD, with an additional case in the third generation (age at onset 64 years). The remaining siblings of this generation were cognitively normal, aged between 35 and 45 years. Apolipoprotein E genotype (*APOE*) of available patients was in all cases ε3//ε3 apart from PR5 (ε3//ε4). Two siblings of PR5, diagnosed with AD, had dementia too, but they were unavailable for sampling.Fig. 1Pedigree of the Italian family with Alzheimer's disease. We report clinical information for the last three generations after the founders. Sex, age at sampling, and apolipoprotein E (*APOE*) genotype of each available family member indicated in the box. The numbers next to subjects with dementia are the age at death. The roman numbers refer to the generation, with the progressive numbers linking to every generation sibling

Sporadic AD cases (*n* = 9) and cognitively normal elderly control subjects (*n* = 191) were included for independent evaluation of the *SEZ6*(R615H) variant frequency by digital droplet PCR (ddPCR).

Patients and healthy control subjects were recruited by the same clinical center, and AD was diagnosed according to international criteria. Healthy control subjects were spouses of patients coming to clinical attention, and they had no sign of neurodegenerative disorders and Mini Mental State Examination (MMSE) scores in the normal range \[[@CR9]\].

Exome sequencing and *APOE* genotyping {#Sec4}
--------------------------------------

The full-exome sequencing of 4811 disease-associated genes (clinical exome) was done starting from 50 ng of DNA diluted in Tris-HCl 10 mM, pH 8.5 (TruSight One Sequencing Panel; Illumina, San Diego, CA, USA), following the manufacturer's instructions. Briefly, capture-based libraries were prepared by pooling three samples per time. The libraries' concentrations were calculated using a Qubit® dsDNA High-Sensitivity Assay Kit (Invitrogen, Carlsbad, CA, USA), and the distribution of DNA fragments for each library was evaluated using a high-sensitivity DNA kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Each library was run on a MiSeq platform (Illumina) using a 2 × 150-bp (300 cycles) configuration on a V3 sequencing flow cell.

Data analysis was performed according to best practice from the bioinformatics community. Raw sequence fragments (reads) were aligned to the reference genome (human, build hg19) with the Burrows-Wheeler alignment tool \[[@CR10]\], followed by post-processing to recalibrate base call quality scores. Variants were called with the Genome Analysis Toolkit \[[@CR11]--[@CR13]\], using the HaplotypeCaller method, then annotated with the Variant Effect Predictor \[[@CR14]\] and loaded into a specialized database \[[@CR15]\] for further analysis. *In silico* mutation impact predictions were extracted from the dbNSFP database \[[@CR16]\]. For computation, we used the "bcbio" pipeline (<https://github.com/chapmanb/bcbio-nextgen>) running on a high-performance computing platform as part of the Cloud4CaRE project. Data files were uploaded to the European Nucleotide Archive with accession number pending.

Selection of candidate variants used the following criteria: (a) depth at least 30×; (b) low frequency in the general population (\< 1% in the 1000 Genomes Project); (c) at least a damaging predicted effect as reported from the dbNSFP; and (d) present in all family members affected by AD or their offspring. The *APOE* genotype was assessed by restriction fragment length polymorphism using the CfoI (Roche, Basel, Switzerland) restriction enzyme, as previously described \[[@CR17]\].

Exome sequencing validation by digital droplet PCR {#Sec5}
--------------------------------------------------

ddPCR experiments were done with the Bio-Rad QX200TM ddPCR system (Bio-Rad Laboratories, Hercules, CA, USA). The mutational assay for *SEZ6* R615H was carried out according to the manufacturer's instructions. Briefly, the TaqMan™ reaction mix, composed of 2× ddPCR Supermix for probes (no deoxyuridine triphosphate), 20× custom target probes for mut SEZ6 (probe sequence: CTACGG**TCA**TGGGCAG-FAM), and 20× reference probes for wild-type SEZ6 (probe sequence: CTACGG**TCG**TGGGCA-HEX), was assembled at a final concentration of 450 nM and 20 ng of DNA in a volume of 20 μl. This reaction mix was added to a DG8 cartridge together with 60 μl of droplet generation oil for probe and used for droplet generation (QX200 droplet generator; Bio-Rad Laboratories). Droplets were then manually transferred to 96-well PCR plates and placed on a thermal cycler (T100 Thermal Cycler; Bio-Rad Laboratories) for the PCR amplification (thermal cycling conditions: 95 °C for 5 min, 95 °C for 30 s, and 55 °C for 1 min, 40 cycles; 98 °C for 10 min and 4 °C infinite; ramping rate 2 °C/s). The PCR plate was then transferred into the QX100 Droplet Reader for the fluorescence measurement of FAM and HEX probes. The numbers of positive and negative droplets were used to calculate the concentrations (copies/μl) of the target and the reference *SEZ6* DNA sequence and their Poisson-based 95% CIs, excluding reactions with fewer than 10,000 total events (positive and negative) (QuantaSoft Analysis pro software 1.0.596; Bio-Rad Laboratories).

For family members and patients with sporadic AD, experiments were run in duplicate; the assay on the healthy population was run once.

Cloning and overexpression of *SEZ6*(R615H) in H4-SW cells {#Sec6}
----------------------------------------------------------

### pSEZ6(R615H) cloning {#Sec7}

Synthetic *SEZ6*(R615H) complementary DNA was provided by GenScript® in pCDNA3.1(+) vector and expanded in competent *Escherichia coli* cells (strain JM109; Promega, Madison, WI, USA). After purification, p*SEZ6*(R615H) was verified through the unique enzymatic restriction site PmeI (New England Biolabs, Hitchin, UK) and agarose gel electrophoresis.

### Cell culture {#Sec8}

H4-SW neuroglioma cells overexpressing human *APP* gene harboring the Swedish (SW) mutation \[[@CR18]\] were grown in DMEM supplemented with 10% FBS, 2 mM [l]{.smallcaps}-glutamine, and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, 300 μg/ml hygromycin B, 10 μg/ml blasticidin-S).

Transient transfection was done using FuGENE® HD Transfection Reagent (Promega), and cells were selected with G418 (1200 μg/ml) after 48 h. For clonal selection of *SEZ6*(R615H) mutants, we picked colonies and analyzed DNA and protein extracts by PCR and Western blotting. Finally, a single-point mutation (G→A) leading to R615H substitution was checked by Sanger sequencing.

PCR for *SEZ6*(R615H) expression in H4-SW cells {#Sec9}
-----------------------------------------------

PCR was run in a 20-μl mixture containing 50 ng of DNA, 0.5 mM each of forward primer 5′-CTACGGTCATGGGCAGGATTG-3′, which contains the single-point mutation (G→A), and the reverse oligonucleotide primer 5′- ATCATGGCAGGTGAGGATGGACT-3′ (metabion, Planegg, Germany); 1× PCR buffer 200 mM Tris-HCl, 500 mM KCl (Thermo Fisher Scientific, Waltham, MA, USA); 2.5 mM deoxynucleotide triphosphate (Thermo Fisher Scientific); 25 mM MgCl~2~ (Thermo Fisher Scientific); and 1 unit of Taq polymerase (Thermo Fisher Scientific). Amplification was done with an initial denaturation at 95 °C for 2 min, followed by 30 cycles of denaturation at 95 °C for 30 s, annealing at 61.7 °C for 30 s, extension at 72 °C for 70 s, and a final 5-min extension at 72 °C. The resulting PCR fragments were resolved by 1% agarose gel electrophoresis (Sigma-Aldrich, St. Louis, MO, USA).

Western blotting for SEZ6 overexpression in H4-SW cells {#Sec10}
-------------------------------------------------------

To assess protein overexpression of *SEZ6* in H4-SW, protein extracts (18 μg) were separated on 8% SDS-PAGE gel and transferred to a nitrocellulose membrane. Blots were developed using horseradish peroxidase-conjugated secondary antibodies and the ECL chemiluminescence system (MerckMillipore, Burlington, MA, USA). All blots were normalized to α-tubulin and quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The following antibodies were used: anti-α-tubulin (1:7500; Abcam, Cambridge, UK) and anti-SEZ6 (1:1000; Aviva Systems Biology, San Diego, CA, USA).

DNA sequencing {#Sec11}
--------------

To verify the presence of the single point mutation, we amplified the region containing the mutated base by PCR with forward primer 5′- GAGATCACAGACTCGGCTG-3′ and the reverse primer 5′- ATCATGGCAGGTGAGGATGGACT-3′ (metabion). The total amount of the generated PCR product was purified using the Wizard SV Gel PCR Clean-Up System (Promega) and sent to a Sanger sequencing service (Eurofins Genomics, Ebersberg, Germany). Output data were analyzed using Chromas Lite 2.01 software.

Aβ(1--42) and Aβ(1--40) in H4-SW cells expressing *SEZ6*(R615H) {#Sec12}
---------------------------------------------------------------

A specific sandwich enzyme-linked immunosorbent assay (ELISA) (Immuno-Biological Laboratories Co., Gunma, Japan) was used to measure Aβ(1--42) and Aβ(1--40) concentrations in conditioned media from cultured H4-SW cells. A total of 150 × 10^3^ cells were seeded in a six-well plate and grown overnight. The next day, the medium was changed, and after 48 h it was collected and immediately frozen after the addition of a broad-spectrum protease inhibitor (Sigma-Aldrich). An aliquot of 100 μl was used for ELISA to assess each value in triplicate.

Western blot analysis for *Sez6* brain expression in 3xTG-AD mice {#Sec13}
-----------------------------------------------------------------

For *Sez6* brain expression analysis, we used 3xTG-AD mice at 3, 9, and 19 months of age. This triple-transgenic model harbors human *PS1*(M146 V), *APP*(SW), and MAPT(P301L) transgenes, and starting from around 9 months of age, mice develop at brain level amyloid plaques and protein tau tangles. They also show early signs of synaptic dysfunction (starting from around 3 months of age), including long-term potentiation alteration \[[@CR19]\]. Strain, age, and sex-matched nontransgenic animals were used as controls. Mice were housed at 23 °C room temperature with food and water *ad libitum* and a 12-h/12-h light/dark cycle. To obtain brain protein extract, the cortex was dissected from a single brain hemisphere and homogenized with ice-cold lysis buffer (pH 7.4) containing 1% Triton X-100 and a broad-range protease inhibitor cocktail. Cortex protein extract (20 μg) was analyzed as described above.

Statistics {#Sec14}
----------

Data analysis was done using Prism® version 6.0 software (GraphPad Software, La Jolla, CA, USA). In vitro and in vivo data were compared using one-way analysis of variance followed by Tukey's post hoc test. Two-tailed levels of significance were used, and *p* \< 0.05 was considered significant.

Results {#Sec15}
=======

Exome sequencing and *APOE* genotyping {#Sec16}
--------------------------------------

To identify variants linked to dementia phenotype, we sequenced DNA samples from family members (healthy and AD cases) and unrelated patients with sporadic AD for a set of over 4000 genes reported as implicated in rare and genetic diseases. Our initial analysis identified 15,745 variants passing our quality control filters (variant depth 30× or more). Many of these were common polymorphisms present in the general population, so we selected only those rare in the European population (\< 1% frequency), lowering the count to 612 (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

To further narrow the search for variants of interest, we used *in silico* analysis to restrict our findings to those predicted as damaging for protein, finding 138 variants (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The majority (96.4%) of possible damaging variants were common between both familial and sporadic AD samples. On the contrary, five variants (3.6%) were exclusive to the family samples (Table [1](#Tab1){ref-type="table"}). In particular, a missense variant in the *SEZ6* neuronal gene (c.1844G\>A, R615H) was present only in the two available AD cases (PR1 and PR5) and in a first-degree relative (PR2, son of PR5). This variant was localized on one of the extracellular CUB domains of the protein \[[@CR20], [@CR21]\] and was predicted to have a high damaging potential (Combined Annotation Dependent Domain \[CADD\] score = 23). This prompted us to further focus on this variant.Table 1Variants exclusive of family members and satisfying the filtering criteriaChrPositionGeneVariantAmino acid change(%)dbSNP\
IDFound in (family code)chr8144,589,984ZC3H3c.1646\
C \> Tp.Ser549\
Leu0.5%rs\
149,025,999*PR 1*, PR 2, PR 3, PR 4, *PR 5*, PR 7, PR 9chr9738,341KANK1c.3391\
G \> Cp.Ala1131Pro0.1%rs\
180,816,986*PR1*, PR3, *PR5*chr1727,286,417**SEZ6**c.1844\
G \> Ap.Arg615\
His0.01%rs\
371,753,097*PR1*, PR2, *PR5*chr2057,598,807TUBB1c.326\
G \> Ap.Gly109\
Glu0.2%rs\
41,303,899*PR1*, PR2, PR3, *PR5*chr2224,717,509SPECC1Lc.562\
C \> Tp.Leu188\
Phe0.9%rs\
56,168,869*PR1*, PR2, PR3, *PR5*, PR9*Chr* Chromosome numberPercentage population frequency refers to data of the European population frequency derived from the 1000 Genomes Project at the time the manuscript was written. *See* the "Methods" section of text for further details. Chromosome positions refer to the hg19 assembly. The gene of interest (SEZ6) is highlighted in bold, and members affected with AD are Italic

Validation of exome sequencing *SEZ6*(R615H) data and variant screening in sporadic AD cases and healthy control subjects {#Sec17}
-------------------------------------------------------------------------------------------------------------------------

Because the clinical exome results indicated a mutation in *SEZ6* gene (c.1844G\>A) as unique to the available family members with AD, we performed an independent validation to confirm the result. Using ddPCR, we tested for the *SEZ6* variant in exome sequencing-positive family members (*n* = 3) and in sporadic AD cases (*n* = 9). To exclude the possibility that the polymorphic variant of *SEZ6* identified could be detected at low frequency in the healthy population, too, the mutational assay was also done in a control group of 191 cognitively healthy people.

Figure [2](#Fig2){ref-type="fig"} shows *SEZ6* mutational analysis of three family members (PR1, PR2, and PR5) and a representative case of sporadic AD (PR11). Wild-type *SEZ6* (green droplets) was detected in all samples, whereas mutated *SEZ6* (blue) was detected only in the PR1, PR2 and PR5 samples. A single event with both wild-type and mutated *SEZ6* was detected in PR11, probably a polymerase artifact.Fig. 2Digital droplet PCR validation of the exome sequencing data. For each patient, a 2D dot plot is shown, reporting the distribution of fluorescence (on the *y*-axis FAM amplitude, and on the *x*-axis HEX amplitude). FAM and HEX are the fluorescent dyes for the *SEZ6* mutant and *SEZ6* wild type, respectively. On the basis of the fluorescence measurements and the droplet distributions, thresholds (*pink lines*) were set to 5000 for the FAM channel (*y*-axis) and 3000 for the HEX channel (*x*-axis). Negative droplets (*gray*), FAM-positive (*blue*), HEX-positive (*green*), and FAM/HEX double-positive (*orange*) droplets are reported for the four cases and no-template control (NTC) analyzed. Each case represents the sum of independent reactions

Regarding a quantitative measure of the *SEZ6* variant, Table [2](#Tab2){ref-type="table"} reports the concentration as the number of target molecules/μl of wild-type and mutant *SEZ6* in all sporadic cases (*n* = 9), in family members (*n* = 3), and in healthy individuals (*n* = 191). Wild-type *SEZ6* copies were detected in all groups. The means of wild-type *SEZ6* copies/μl were 564, 258, and 130 in the healthy control group, sporadic AD cases, and family members, respectively. A high concentration of mutant *SEZ6* was detected in family member samples. The simultaneous presence of the wild-type and the mutated form of *SEZ6*, with ratios (mutated *SEZ6* to wild-type *SEZ6*) ranging from 0.95 to 1.1, confirmed the heterozygous nature of the *SEZ6* C\>T 27,286,417--27,186,418 substitution.Table 2Mutant *SEZ6* assay by digital droplet PCR in healthy control subjects, patients with sporadic Alzheimer's disease, and family membersHealthy population (n = 191)Sporadic AD cases (n = 9)Family members (n = 3)SampleTargetConcentration\
(copies/μl)TargetConcentration\
(copies/μl)SampleTargetConcentration (copies/μl)TargetConcentration (copies/μl)SampleTargetConcentration\
(copies/μl)TargetConcentration (copies/μl)RATIO (mut/wt)6MUT SEZ6N.D.WT SEZ617PR3MUT SEZ6N.D.WT SEZ6239*PR1*MUT SEZ6116WT SEZ61031.137MUT SEZ6N.D.WT SEZ614MUT SEZ6N.D.WT SEZ6226MUT SEZ6114WT SEZ61200.958MUT SEZ6N.D.WT SEZ611PR4MUT SEZ6N.D.WT SEZ6220PR2MUT SEZ6130WT SEZ61301.009MUT SEZ6N.D.WT SEZ659MUT SEZ6N.D.WT SEZ6224MUT SEZ6131WT SEZ61271.0311MUT SEZ6N.D.WT SEZ641PR6MUT SEZ6N.D.WT SEZ6267*PR5*MUT SEZ6149WT SEZ61530.9712MUT SEZ6N.D.WT SEZ649MUT SEZ6N.D.WT SEZ6261MUT SEZ6154WT SEZ61521.0113MUT SEZ6N.D.WT SEZ636PR7MUT SEZ6N.D.WT SEZ633114MUT SEZ6N.D.WT SEZ629MUT SEZ6N.D.WT SEZ637116MUT SEZ6N.D.WT SEZ629PR8MUT SEZ6N.D.WT SEZ630717MUT SEZ6N.D.WT SEZ627MUT SEZ6N.D.WT SEZ630318MUT SEZ6N.D.WT SEZ643PR9MUT SEZ6N.D.WT SEZ625419MUT SEZ6N.D.WT SEZ630MUT SEZ6N.D.WT SEZ626621MUT SEZ6N.D.WT SEZ635PR10MUT SEZ6N.D.WT SEZ623922MUT SEZ6N.D.WT SEZ653MUT SEZ6N.D.WT SEZ627323MUT SEZ6N.D.WT SEZ637PR11MUT SEZ6N.D.WT SEZ623324MUT SEZ6N.D.WT SEZ645MUT SEZ6N.D.WT SEZ622825MUT SEZ6N.D.WT SEZ632PR12MUT SEZ6N.D.WT SEZ621227MUT SEZ6N.D.WT SEZ626MUT SEZ6N.D.WT SEZ619028MUT SEZ6N.D.WT SEZ64729MUT SEZ6N.D.WT SEZ64830MUT SEZ6N.D.WT SEZ63034MUT SEZ6N.D.WT SEZ63036MUT SEZ6N.D.WT SEZ64938MUT SEZ6N.D.WT SEZ63239MUT SEZ6N.D.WT SEZ63441MUT SEZ6N.D.WT SEZ67442MUT SEZ6N.D.WT SEZ64344MUT SEZ6N.D.WT SEZ65346MUT SEZ6N.D.WT SEZ66451MUT SEZ6N.D.WT SEZ65552MUT SEZ6N.D.WT SEZ61953MUT SEZ6N.D.WT SEZ63260MUT SEZ6N.D.WT SEZ64661MUT SEZ6N.D.WT SEZ64462MUT SEZ6N.D.WT SEZ66464MUT SEZ6N.D.WT SEZ65566MUT SEZ6N.D.WT SEZ64567MUT SEZ6N.D.WT SEZ64669MUT SEZ6N.D.WT SEZ64870MUT SEZ6N.D.WT SEZ64571MUT SEZ6N.D.WT SEZ66772MUT SEZ6N.D.WT SEZ65774MUT SEZ6N.D.WT SEZ65489MUT SEZ6N.D.WT SEZ64790MUT SEZ6N.D.WT SEZ67891MUT SEZ6N.D.WT SEZ664.3101MUT SEZ6N.D.WT SEZ6283112MUT SEZ6N.D.WT SEZ6524113MUT SEZ6N.D.WT SEZ61451114MUT SEZ6N.D.WT SEZ6962115MUT SEZ6N.D.WT SEZ6534118MUT SEZ6N.D.WT SEZ6527119MUT SEZ6N.D.WT SEZ61691120MUT SEZ6N.D.WT SEZ6359129MUT SEZ6N.D.WT SEZ6186130MUT SEZ6N.D.WT SEZ6258133MUT SEZ6N.D.WT SEZ6232135MUT SEZ6N.D.WT SEZ6373137MUT SEZ6N.D.WT SEZ6319144MUT SEZ6N.D.WT SEZ6310151MUT SEZ6N.D.WT SEZ6396152MUT SEZ6N.D.WT SEZ6180160MUT SEZ6N.D.WT SEZ6574162MUT SEZ6N.D.WT SEZ6400163MUT SEZ6N.D.WT SEZ6142164MUT SEZ6N.D.WT SEZ639170MUT SEZ6N.D.WT SEZ696179MUT SEZ6N.D.WT SEZ694180MUT SEZ6N.D.WT SEZ627182MUT SEZ6N.D.WT SEZ61406184MUT SEZ6N.D.WT SEZ61994185MUT SEZ6N.D.WT SEZ6161192MUT SEZ6N.D.WT SEZ614.5193MUT SEZ6N.D.WT SEZ61740197MUT SEZ6N.D.WT SEZ6185198MUT SEZ6N.D.WT SEZ6250199MUT SEZ6N.D.WT SEZ6145200MUT SEZ6N.D.WT SEZ6132202MUT SEZ6N.D.WT SEZ6663205MUT SEZ6N.D.WT SEZ6658206MUT SEZ6N.D.WT SEZ6118210MUT SEZ6N.D.WT SEZ6103212MUT SEZ6N.D.WT SEZ623214MUT SEZ6N.D.WT SEZ6385215MUT SEZ6N.D.WT SEZ6125219MUT SEZ6N.D.WT SEZ6223223MUT SEZ6N.D.WT SEZ6316228MUT SEZ6N.D.WT SEZ6109233MUT SEZ6N.D.WT SEZ6385237MUT SEZ6N.D.WT SEZ6767240MUT SEZ6N.D.WT SEZ6318241MUT SEZ6N.D.WT SEZ615243MUT SEZ6N.D.WT SEZ630245MUT SEZ6N.D.WT SEZ6166247MUT SEZ6N.D.WT SEZ6161251MUT SEZ6N.D.WT SEZ6164253MUT SEZ6N.D.WT SEZ6491254MUT SEZ6N.D.WT SEZ6772255MUT SEZ6N.D.WT SEZ6771257MUT SEZ6N.D.WT SEZ6148261MUT SEZ6N.D.WT SEZ6875263MUT SEZ6N.D.WT SEZ6381267MUT SEZ6N.D.WT SEZ6442270MUT SEZ6N.D.WT SEZ6368275MUT SEZ6N.D.WT SEZ6317276MUT SEZ6N.D.WT SEZ6368277MUT SEZ6N.D.WT SEZ6186278MUT SEZ6N.D.WT SEZ663279MUT SEZ6N.D.WT SEZ6234287MUT SEZ6N.D.WT SEZ699293MUT SEZ6N.D.WT SEZ6125324MUT SEZ6N.D.WT SEZ6605325MUT SEZ6N.D.WT SEZ6153326MUT SEZ6N.D.WT SEZ6692327MUT SEZ6N.D.WT SEZ6713328MUT SEZ6N.D.WT SEZ6391332MUT SEZ6N.D.WT SEZ6759333MUT SEZ6N.D.WT SEZ6661337MUT SEZ6N.D.WT SEZ6798338MUT SEZ6N.D.WT SEZ6903340MUT SEZ6N.D.WT SEZ640341MUT SEZ6N.D.WT SEZ6274342MUT SEZ6N.D.WT SEZ6240344MUT SEZ6N.D.WT SEZ6209345MUT SEZ6N.D.WT SEZ6873348MUT SEZ6N.D.WT SEZ62330350MUT SEZ6N.D.WT SEZ6387351MUT SEZ6N.D.WT SEZ6430353MUT SEZ6N.D.WT SEZ6360360MUT SEZ6N.D.WT SEZ6473361MUT SEZ6N.D.WT SEZ6553362MUT SEZ6N.D.WT SEZ62470363MUT SEZ6N.D.WT SEZ6889366MUT SEZ6N.D.WT SEZ61990367MUT SEZ6N.D.WT SEZ6452368MUT SEZ6N.D.WT SEZ61736369MUT SEZ6N.D.WT SEZ61436375MUT SEZ6N.D.WT SEZ6588376MUT SEZ6N.D.WT SEZ6544377MUT SEZ6N.D.WT SEZ6623401MUT SEZ6N.D.WT SEZ6803404MUT SEZ6N.D.WT SEZ6494406MUT SEZ6N.D.WT SEZ6200407MUT SEZ6N.D.WT SEZ6482408MUT SEZ6N.D.WT SEZ6105409MUT SEZ6N.D.WT SEZ63260418MUT SEZ6N.D.WT SEZ6190422MUT SEZ6N.D.WT SEZ61325430MUT SEZ6N.D.WT SEZ6772434MUT SEZ6N.D.WT SEZ61233435MUT SEZ6N.D.WT SEZ61844440MUT SEZ6N.D.WT SEZ690446MUT SEZ6N.D.WT SEZ6745451MUT SEZ6N.D.WT SEZ61366453MUT SEZ6N.D.WT SEZ61185454MUT SEZ6N.D.WT SEZ62950466MUT SEZ6N.D.WT SEZ6329468MUT SEZ6N.D.WT SEZ6681493MUT SEZ6N.D.WT SEZ680497MUT SEZ6N.D.WT SEZ6154499MUT SEZ6N.D.WT SEZ6128501MUT SEZ6N.D.WT SEZ61814511MUT SEZ6N.D.WT SEZ6547512MUT SEZ6N.D.WT SEZ648.2513MUT SEZ6N.D.WT SEZ640.8514MUT SEZ6N.D.WT SEZ61019519MUT SEZ6N.D.WT SEZ61382520MUT SEZ6N.D.WT SEZ6791521MUT SEZ6N.D.WT SEZ61858522MUT SEZ6N.D.WT SEZ62180523MUT SEZ6N.D.WT SEZ61849531MUT SEZ6N.D.WT SEZ62110532MUT SEZ6N.D.WT SEZ63030535MUT SEZ6N.D.WT SEZ61096537MUT SEZ6N.D.WT SEZ61941538MUT SEZ6N.D.WT SEZ678539MUT SEZ6N.D.WT SEZ6917542MUT SEZ6N.D.WT SEZ61650543MUT SEZ6N.D.WT SEZ6937545MUT SEZ6N.D.WT SEZ61423546MUT SEZ6N.D.WT SEZ6818549MUT SEZ6N.D.WT SEZ61196550MUT SEZ6N.D.WT SEZ6716558MUT SEZ6N.D.WT SEZ6845567MUT SEZ6N.D.WT SEZ6724570MUT SEZ6N.D.WT SEZ6765571MUT SEZ6N.D.WT SEZ62290574MUT SEZ6N.D.WT SEZ6790575MUT SEZ6N.D.WT SEZ61399578MUT SEZ6N.D.WT SEZ61293580MUT SEZ6N.D.WT SEZ6947*ND* Not detectableAlzheimer's disease cases are underlined. For each group, patient code, digital droplet PCR target, and the calculated concentration (copies/μl) are reported. For the last group, the ratio, defined as concentration mutant *SEZ6*/concentration wild-type *SEZ6*, is also reported

Aβ peptide generation in H4-SW cells {#Sec18}
------------------------------------

Three different H4-SW stable clonal lines (C3, C4, and C13) transfected with a pCDNA3.1 plasmid coding for *SEZ6*(R615H) mutant were selected, and the presence of the variant at DNA level was confirmed by allele-specific PCR and sequencing (data not shown). The effect of the R615H substitution on Aβ(1--42) and Aβ(1--40) production by H4-SW cells was assessed in conditioned media from cultured H4-SW(R615H) in comparison to H4-SW cells (untransfected or mock-transfected with an empty pCDNA3.1 vector) (Fig. [3a](#Fig3){ref-type="fig"}). The mean concentration of released Aβ(1--42), normalized to cell total protein content, was significantly lower in C4 and C13 than in controls, whereas for the C3 line, there was a trend in the same direction (*p* = 0.07). The Aβ(1--40) assay showed no differences (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3Evaluation of *SEZ6* relevance for Alzheimer's disease (AD) mechanisms in *in vitro* and *in vivo* models. **a** Quantification by enzyme-linked immunosorbent assay of soluble amyloid-β 1--40 (Aβ~1--40~) in conditioned media from H4-SW clonal lines (C3, C4, and C13) overexpressing *SEZ6*(R615H). The amyloid peptide concentration was normalized to the total protein content of the producing cells of each replicate. Measures are the mean ± SD of three independent wells. *H4-SW* Untransfected control; *Ø* H4-SW control transfected with pCDNA3.1 empty vector. **b** Same as in (**a**) except for the assessment of Aβ~1--42~ soluble form. \* *p* \< 0.05; \*\*\* *p* \< 0.001, one-way analysis of variance (ANOVA) and post hoc test; ^\#^ *p* \< 0.05 vs. C4 and *p* \< 0.01 vs. C13, one-way ANOVA and post hoc test. **c** Representative Western blotting for Sez6 protein detection in brain cortical extract from 3xTG-AD mice. Mice were killed at ages 3, 9, or 19 months, and *Sez6* expression was assessed in transgenic and matched nontransgenic (NTG) animals. Each group was composed of three mice, and every animal was loaded in duplicate in the SDS-PAGE experiment. \* Unspecific signal. **d** Densitometric quantification of all Western blot analysis data for Sez6 protein cortical expression (*n* = 3 mice/group) using ImageJ software. Each signal was normalized to the corresponding α-tubulin band to control for unequal protein loading. Results are expressed as a percentage of the youngest group (3 months) \* *p* \< 0.05, one-way ANOVA and post hoc test. *mo.* Months from birth

*Sez6* brain expression in 3xTG-AD mice {#Sec19}
---------------------------------------

Given that few experimental data linked *SEZ6* to AD, we also examined murine *Sez6* expression in a transgenic line model of AD (3xTG-AD), in comparison with age-matched nontransgenic controls (NTG) (Fig. [3c](#Fig3){ref-type="fig"} and [d](#Fig3){ref-type="fig"}). Mice were killed at ages ranging from 3 to 19 months, and Sez6 protein expression was assessed at brain cortical level. Sez6 protein markedly decreased with age, particularly between 3 and 19 months. However, this reduction was common to both the 3xTG-AD and NTG lines and thus not unique to the AD model.

Discussion {#Sec20}
==========

Pathogenic mutations in *APP*, *PSEN1*, or *PSEN2* genes are linked to FAD \[[@CR3], [@CR4]\]. *PSEN1* mutations are responsible for about 60% of the genetic cases of AD, and 286 pathogenic variants have been described in the three above-cited genes \[[@CR22]\]. We report an Italian family with AD that we previously screened by denaturing high-performance liquid chromatography (data not shown) for *APP*, *PSEN1,* or *PSEN2* mutations with no results. Considering that rare variants in other genes have been associated with AD \[[@CR7]\], we decided to perform targeted exome-sequencing analysis that yielded a large number of variants; in order to identify those closely related to the disease, we employed a recursive filtering strategy. This strategy was based on the removal of high-frequency (\> 1%) variants using a public database (1000 Genomes Project) with *in silico* prediction software (SIFT, PolyPhen2, CADD) to exclude potentially harmless mutations and focus on variants present in FAD but not sporadic AD samples. We gave priority to the *SEZ6*(R615H) variant among those reported in Table [1](#Tab1){ref-type="table"}, considering that *SEZ6* has already been reported as relevant for molecular mechanisms involved in AD pathogenesis, because it is a substrate of the BACE-1 enzyme (β-secretase), affects synapse formation, and is reduced in the cerebrospinal fluid of patients with AD, as revealed by a proteomic study \[[@CR23]--[@CR25]\]. *SEZ6* gene mutations have been also reported in association with febrile seizures, and *SEZ6* was proposed as a candidate gene for epilepsy \[[@CR26], [@CR27]\]. Moreover, *SEZ6* mutations were found in cases of childhood-onset schizophrenia \[[@CR28]\]. The rare variant R615H (rs371753097, C/T) was reported in the 1000 Genomes Project as absent in Toscani in Italy (TSI) population and had a frequency in the whole project of 0.0002 \[[@CR29]\]. Another interesting genetic variant we found by exome sequencing that is deserving of attention is A1131P in the *KANK1* gene \[[@CR30]\], which was present in the two AD cases (PR1 and PR5) and in PR3, sibling of PR1. However, PR3 did not have dementia at sampling (age 67 years), and her clinical state is currently unchanged, even though we are not able to exclude a possible later onset. The human *KANK1* gene (alias ANKRD15) was originally described to be a tumor suppressor in renal cell carcinoma, and it encodes an ankyrin repeat domain-containing protein (Kank). It belongs to a family of four homologous members that have a role in actin stress fiber formation and renal pathophysiology \[[@CR31], [@CR32]\]. There is no reported interaction of *KANK1* with *SEZ6* or AD-related genes. However, a role of *KANK1* mutation or deletion was reported in cerebral palsy spastic quadriplegic type 2, a central nervous system developmental disorder \[[@CR33]\]. Moreover, to the best of our knowledge, no data associate *KANK1* with AD.

In our study's family, we were able to correlate the AD pathology to R615H presence, which was found in the two available AD-affected members and one first-degree relative of an AD case, whose age at sampling in 2003 (PR2, 37 years) was far below the family age of onset (range, 60--70 years) to expect clinical signs. The current clinical diagnosis of PR2 (51 years) is unchanged. We also confirmed that R615H frequency is very low (\< 1%) in the Italian population, because we were unable to detect the variant in 200 family-unrelated subjects.

Because it is a common finding that AD pathogenic mutations increase Aβ(1--42) peptide generation \[[@CR34]\], we examined the effect of the R615H variant in a cell model in this respect. In the H4-SW line, we noticed a decrease in Aβ(1--42), whereas Aβ(1--40) was unchanged. However, the increase of Aβ(1--42) in association with FAD-linked mutations is not always replicated. In fact, some presenilin mutants with proved pathologic action did not increase Aβ(1--42) but acted on other Aβ peptide generation or even had no impact on this proteolytic cleavage. In the latter case, the hypothesis is that the mutation affects important functions of presenilin other than the γ-secretase activity \[[@CR35], [@CR36]\]. It is worth underlining that we found a peculiar biochemical effect of the *PSEN1* mutation E318G that increased Aβ(1--40) only in cultured skin primary fibroblasts \[[@CR17]\]. Our failure to detect an increase of Aβ(1--42) might depend on the reported role of SEZ6 protein as substrate for BACE-1 \[[@CR23]\], so its overexpression may be competitive for *APP* in the cell model tested. We need further experiments to clarify the role of the R615H variant in this context.

Finally, we followed *SEZ6* cortical expression in a mouse model of AD (3xTG-AD). Considering that it changed similarly in 3xTG-AD and control mice, we were unable to link this result to AD-specific patterns, but we did notice a decrease of SEZ6 protein with age, in agreement with this gene's reported role in brain development \[[@CR37], [@CR38]\]. A damaging mutation (as R615H is predicted to be) may have an impact on the protein activity from birth, with possible neuropathologic outcomes, likely in combination with other triggering factors, also considering the reported role of *SEZ6* in dendritic spine dynamics and cognition \[[@CR39]\].

This study has limitations, mainly linked to the unavailability of genomic DNA from all the family's AD-affected members alive at sampling. Moreover, we decided to use a targeted exome-sequencing strategy that, on one hand, gave us clinical data supporting a rational choice of candidate variants to be prioritized, but on the other hand, prevented us from ruling out that additional coding mutations in genes not included in our panel may be linked to AD phenotype, thus acting in synergy with *SEZ6 (R615H)*.

Conclusions {#Sec21}
===========

In summary, by using a targeted exome-sequencing approach, we discovered a rare *SEZ6* variant exclusive to AD members of a large Italian family carrying no typical FAD-linked mutations that might have a role in disease onset, in particular taking into account the already described involvement of *SEZ6* in AD pathogenic mechanisms linked to amyloid-β (A4) precursor protein (*APP*) and brain physiology, even though the exact molecular pathway linking *SEZ6* to AD is still unclear.
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Additional file 1:Table reporting the sequencing results of DNA from PR family members and unrelated sporadic AD cases, including only rare variants in the European population (frequency less than 1%) \[low frequency page\]. The same reults were further filtered to show variants with predicted damaging action \[predicted damage page\]. (XLSX 85 kb)
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